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Editorial comment on ‘Preventing LVAD implantation by
early short-term mechanical support and prolonged
inodilator therapy: a case series with acute refractory car-
diogenic shock treated with veno-arterial ECMO and
optimised medical strategy’
J.J. Brugts, O. Manintveld, A. Constantinescu, D. Donker,
R. van Thiel, K. Nieman, L. Jewbali, F. Zijlstra, K. Caliskan
In this issue of the Netherlands Heart Journal, Brugts et al.
describe a series of cases with acute severe refractory cardio-
genic shock [1]. All three patients had no relevant cardiac
history and were initially referred for durable left ventricular
assist device (LVAD) implantation and/or heart transplanta-
tion (HTx). Dilated cardiomyopathy was diagnosed in two
patients (one with an unknown cause, one due to alcohol/
toxicity), while parvo B10 viral myocarditis was confirmed
by biopsy in the other patient. Veno-arterial extracorporal life
support (VA-ECLS) was started because a high dose of pos-
itive inotropes and intra-aortic balloon pump (IABP) were
insufficient. Low-dose beta blocker and ACE inhibition were
initiated early and titrated in combination with phosphodies-
terase inhibition (enoximone). In all three cases cardiac func-
tion recovered and the patients were successfully weaned from
VA-ECLS without any signs of relapse in up to 3.5 years of
follow-up.
The authors conclude that the combination of extracorpo-
real membrane oxygenation (ECMO) and early introduc-
tion of heart failure medication under the umbrella of
phosphodiesterase inhibition provided momentum to survive
and prevent LVAD implantation.
The introduction of extracorporal life support in the 1970s
has defined the standard of care in so-called ‘crash and burn’
(INTERMACS 1) patients [2]. The clinical management of
this patient category is still hampered by the high mortality
rate but also by the lack of accurate guidelines to confirm the
appropriate patients and timing for mechanical circulatory
support [3].
The rise of durable LVADs has significantly improved
survival in end-stage heart failure and has provided a success-
ful bridge to transplantation [4]. However, results of durable
LVADs as bridge to recovery are poor, with maximal
sustained recovery rates of 20.5 % recorded by Birks in a
large cohort of 92 patients with an aggressive supporting
pharmacological regimen [5, 6]. Though infrequent, cardiac
recovery is primarily seen in non-ischaemic cardiomyopathy
with divided aetiology between myocarditis, peripartum car-
diomyopathy and idiopathic, potentially reversible causes of
heart failure [5–7].
Analysis on survival after implantation of a durable
LVAD in different INTERMACS categories revealed dra-
matically high mortality rates in INTERMACS profiles 1
and 2, compared with less critically ill patients [8]. This
finding gave rise to the current applied strategy of short-
term mechanical circulatory support in ‘crash and burn’
patients [2]. Especially in potentially reversible causes of
cardiogenic shock, temporary ECLS can be sufficient.
When recovery does not meet explantation criteria a long-
term device and/or heart transplantation is still indicated.
Although the strategy of preventing LVAD implantation by
early short-term mechanical support and prolonged
inodilator therapy is described in the present case series as
a novel approach, clinicians worldwide are already initially
treating INTERMACS profile 1 patients with short-term
mechanical support to prevent mortality.
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To promote reversal of heart failure, different combinations
of pharmacological strategies have been investigated. For ex-
ample, sustained recovery was seen in the majority of a small
group of patients with acute and severe non-ischaemic cardio-
myopathy without active myocarditis treated with a strict phar-
macological treatment consisting of the β2-agonist clenbuterol
[9]. From the investigated combination of heart failure medica-
tion with enoximone, no conclusion can be drawn. Widely, the
benefit of beta blockers in unstable severe heart failure is lacking
evidence, due to routine exclusions in studies, and one should be
extremely cautious in case of right ventricular failure [3, 10].
A recent retrospective study on early heart failure pharma-
cotherapy in ongoing cardiogenic shock compared patients
who did and did not receive heart failure therapy within 24 h
of admission. In comparison with no therapy, administration
of β-blocker was significantly associated with an increased
30-day mortality and longer median duration of shock [11].
Rather than preventing the pathway of long-term LVAD
support, the reported cases elegantly describe recovery of
heart failure with state of the art treatment with ECLS in
potentially reversible causes of cardiogenic shock. The addi-
tive value of the pharmacological regimen cannot be conclud-
ed from this series without a control group. Controlled studies
are necessary to examine the value (or harm) of early intro-
duction of heart failure medication.
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